223 related articles for article (PubMed ID: 30808322)
1. Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
Shirasawa M; Fukui T; Kusuhara S; Hiyoshi Y; Nakahara Y; Nishinarita N; Igawa S; Naoki K
BMC Cancer; 2019 Feb; 19(1):163. PubMed ID: 30808322
[TBL] [Abstract][Full Text] [Related]
2. Second-line Chemotherapy for Patients with Small Cell Lung Cancer and Interstitial Lung Disease.
Fujimoto D; Shimizu R; Kato R; Sato Y; Kogo M; Ito J; Teraoka S; Otoshi T; Nagata K; Nakagawa A; Otsuka K; Katakami N; Tomii K
Anticancer Res; 2015 Nov; 35(11):6261-6. PubMed ID: 26504060
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of preexisting interstitial lung disease in Japanese patients with small-cell lung cancer.
Togashi Y; Masago K; Handa T; Tanizawa K; Okuda C; Sakamori Y; Nagai H; Kim YH; Mishima M
Clin Lung Cancer; 2012 Jul; 13(4):304-11. PubMed ID: 22169479
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer.
Nakao S; Yamaguchi K; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Iwamoto H; Fujitaka K; Hamada H; Hattori N
Anticancer Res; 2019 Oct; 39(10):5725-5731. PubMed ID: 31570474
[TBL] [Abstract][Full Text] [Related]
5. Glasgow prognostic score for prediction of chemotherapy-triggered acute exacerbation interstitial lung disease in patients with small cell lung cancer.
Kikuchi R; Takoi H; Tsuji T; Nagatomo Y; Tanaka A; Kinoshita H; Ono M; Ishiwari M; Toriyama K; Kono Y; Togashi Y; Yamaguchi K; Yoshimura A; Abe S
Thorac Cancer; 2021 Jun; 12(11):1681-1689. PubMed ID: 33939332
[TBL] [Abstract][Full Text] [Related]
6. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
7. [Clinical features of acute exacerbation of interstitial pneumonia associated with lung cancer after chemotherapy].
Sato K; Shimaoka Y; Hayashi Y; Suzuki N; Ebe Y
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1493-7. PubMed ID: 19755819
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
[TBL] [Abstract][Full Text] [Related]
9. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
10. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer.
Kenmotsu H; Naito T; Kimura M; Ono A; Shukuya T; Nakamura Y; Tsuya A; Kaira K; Murakami H; Takahashi T; Endo M; Yamamoto N
J Thorac Oncol; 2011 Jul; 6(7):1242-6. PubMed ID: 21623239
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for in-hospital mortality in patients with advanced lung cancer with interstitial pneumonia undergoing systemic chemotherapy: A retrospective and observational study using a nationwide administrative database in Japan.
Shiraishi T; Oda K; Yamasaki K; Kido T; Sennari K; Mukae H; Ohtani M; Fujino Y; Matsuda S; Fushimi K; Yatera K
Thorac Cancer; 2022 Jan; 13(2):236-246. PubMed ID: 34865321
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of post-progression survival on overall survival in elderly patients with extensive disease small-cell lung cancer.
Imai H; Mori K; Watase N; Kazama T; Fujimoto S; Kaira K; Yamada M; Minato K
Thorac Cancer; 2016 Nov; 7(6):655-662. PubMed ID: 27755823
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic value of pretreatment serum LDH in patients with limited disease small-cell lung carcinoma.
Stokkel MP; Van Eck-Smit BL; Zwinderman AH; Willems LN; Pauwels EK
Int J Biol Markers; 1997; 12(4):162-7. PubMed ID: 9582606
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease.
Yoshida T; Yoh K; Goto K; Niho S; Umemura S; Ohmatsu H; Ohe Y
Anticancer Res; 2013 Mar; 33(3):1175-9. PubMed ID: 23482799
[TBL] [Abstract][Full Text] [Related]
15. Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer.
Shirasawa M; Fukui T; Kusuhara S; Harada S; Nishinarita N; Hiyoshi Y; Ishihara M; Kasajima M; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
PLoS One; 2019; 14(4):e0214599. PubMed ID: 31002722
[TBL] [Abstract][Full Text] [Related]
16. High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.
Wang C; Jin S; Xu S; Cao S
Lung; 2020 Apr; 198(2):405-414. PubMed ID: 32016563
[TBL] [Abstract][Full Text] [Related]
17. Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.
Akaike K; Saruwatari K; Okabayashi H; Hamada S; Jodai Y; Jodai T; Sakata S; Iyama S; Sato R; Iriki T; Tomita Y; Saeki S; Ichiyasu H; Fujii K
Anticancer Res; 2018 Nov; 38(11):6543-6550. PubMed ID: 30396984
[TBL] [Abstract][Full Text] [Related]
18. Pretherapeutic Inflammation Predicts Febrile Neutropenia and Reduced Progression-Free Survival after First-Line Chemotherapy in SCLC.
Kauffmann-Guerrero D; Kahnert K; Syunyaeva Z; Tufman A; Huber RM
Oncol Res Treat; 2018; 41(9):506-512. PubMed ID: 30086542
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of the serum neuron specific enolase and lactate dehydrogenase in small cell lung cancer patients receiving first-line platinum-based chemotherapy.
Liu X; Zhang W; Yin W; Xiao Y; Zhou C; Hu Y; Geng S
Medicine (Baltimore); 2017 Nov; 96(46):e8258. PubMed ID: 29145241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
